IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Boone Capital Management LLC

Boone Capital Management LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,141 shares of the medical research company's stock after selling 10,441 shares during the quarter. IQVIA accounts for 3.8% of Boone Capital Management LLC's portfolio, making the stock its 11th largest holding. Boone Capital Management LLC's holdings in IQVIA were worth $11,229,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Cadian Capital Management LP purchased a new position in IQVIA in the 4th quarter worth about $78,604,000. Cary Street Partners Financial LLC purchased a new position in shares of IQVIA in the fourth quarter worth approximately $1,422,000. Chapman Financial Group LLC acquired a new stake in shares of IQVIA during the fourth quarter valued at approximately $1,061,000. Baird Financial Group Inc. lifted its position in shares of IQVIA by 2.2% in the 4th quarter. Baird Financial Group Inc. now owns 61,023 shares of the medical research company's stock valued at $11,992,000 after acquiring an additional 1,319 shares in the last quarter. Finally, Bank of America Corp DE grew its position in IQVIA by 30.3% during the 4th quarter. Bank of America Corp DE now owns 1,255,535 shares of the medical research company's stock worth $246,725,000 after purchasing an additional 291,816 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on IQV shares. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Citigroup decreased their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Barclays reiterated an "equal weight" rating and issued a $170.00 target price (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Truist Financial lowered their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Finally, Morgan Stanley increased their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $237.62.

IQVIA Price Performance

Shares of IQVIA stock opened at $152.31 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The firm has a fifty day simple moving average of $166.75 and a 200-day simple moving average of $190.17. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $26.85 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.